The global market for Preventable Vaccines was valued at US$86.9 Billion in 2024 and is projected to reach US$92.9 Billion by 2030, growing at a CAGR of 1.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The development and distribution of vaccines involve complex research and rigorous testing to ensure safety and efficacy before they are approved for public use. Over the years, vaccine technology has evolved from live-attenuated and inactivated forms to more sophisticated subunit, recombinant, conjugate, and mRNA vaccines. Each type is tailored to fight different pathogens in the most effective way possible, with newer technologies, such as mRNA vaccines, offering rapid development in response to emerging infectious diseases like COVID-19. Furthermore, the advent of vaccine platforms that can be quickly adapted to new pathogens has revolutionized the field, particularly in response to pandemics. Besides human health, vaccines are also crucial in veterinary practices, protecting livestock from diseases and thereby supporting food security and agricultural economies.
The growth in the preventable vaccines market is driven by several factors, including technological advancements in vaccine development, an increase in government and private funding for immunization programs, and a heightened awareness of the importance of vaccinations. Technological innovations have led to more effective and safer vaccines, with developments in adjuvants and delivery systems improving the immune response and reducing side effects. The global expansion of routine immunization programs, supported by international health organizations and governments, has increased the demand for vaccines, especially in underdeveloped and developing regions. Additionally, consumer behavior has shifted significantly in recent years, with a growing preference for preventive healthcare measures, further spurred by the COVID-19 pandemic’s demonstration of the critical role of vaccinations in controlling infectious diseases. The market's expansion is also facilitated by the rise in travel and migration, which increases the exposure to different pathogens, thereby boosting the need for broader immunization coverage. This dynamic market is expected to continue growing as new vaccine technologies and international health initiatives expand to meet the challenges of existing and emerging infectious diseases.
Global Preventable Vaccines Market - Key Trends and Drivers Summarized
Preventable vaccines are essential tools in the global health arsenal, designed to protect individuals and populations from infectious diseases by stimulating the immune system to recognize and fight pathogens effectively. These biological preparations introduce a harmless form of a disease-causing microorganism or one of its components into the body, prompting the immune system to respond and build immunity without causing the actual disease. This mechanism enables the immune system to respond more rapidly and effectively should the individual ever be exposed to the real pathogen. The routine vaccine schedule, which includes immunizations against diseases such as measles, mumps, rubella, diphtheria, and pertussis, is a cornerstone of public health policy worldwide. Vaccination has led to the eradication or significant reduction of many life-threatening diseases and continues to be a critical strategy in preventing outbreaks and epidemics.The development and distribution of vaccines involve complex research and rigorous testing to ensure safety and efficacy before they are approved for public use. Over the years, vaccine technology has evolved from live-attenuated and inactivated forms to more sophisticated subunit, recombinant, conjugate, and mRNA vaccines. Each type is tailored to fight different pathogens in the most effective way possible, with newer technologies, such as mRNA vaccines, offering rapid development in response to emerging infectious diseases like COVID-19. Furthermore, the advent of vaccine platforms that can be quickly adapted to new pathogens has revolutionized the field, particularly in response to pandemics. Besides human health, vaccines are also crucial in veterinary practices, protecting livestock from diseases and thereby supporting food security and agricultural economies.
The growth in the preventable vaccines market is driven by several factors, including technological advancements in vaccine development, an increase in government and private funding for immunization programs, and a heightened awareness of the importance of vaccinations. Technological innovations have led to more effective and safer vaccines, with developments in adjuvants and delivery systems improving the immune response and reducing side effects. The global expansion of routine immunization programs, supported by international health organizations and governments, has increased the demand for vaccines, especially in underdeveloped and developing regions. Additionally, consumer behavior has shifted significantly in recent years, with a growing preference for preventive healthcare measures, further spurred by the COVID-19 pandemic’s demonstration of the critical role of vaccinations in controlling infectious diseases. The market's expansion is also facilitated by the rise in travel and migration, which increases the exposure to different pathogens, thereby boosting the need for broader immunization coverage. This dynamic market is expected to continue growing as new vaccine technologies and international health initiatives expand to meet the challenges of existing and emerging infectious diseases.
Report Scope
The report analyzes the Preventable Vaccines market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments
Vaccine Type (Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Other Vaccine Types); Disease Type (Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease, Influenza Disease, Measles & Rubella Disease, Other Disease Types); Distribution Channel (Public Distribution Channel, Private Distribution Channel).Geographic Regions/Countries
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Live / Attenuated Vaccines segment, which is expected to reach US$34.1 Billion by 2030 with a CAGR of a 1.2%. The Inactivated Vaccines segment is also set to grow at 1.6% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $23.6 Billion in 2024, and China, forecasted to grow at an impressive 2.1% CAGR to reach $16.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AstraZeneca PLC, Bharat Biotech International Ltd., Boehringer Ingelheim International GmbH, Daiichi Sankyo Co., Ltd., Emergent BioSolutions, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Preventable Vaccines Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Preventable Vaccines Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Preventable Vaccines Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 46 major companies featured in this Preventable Vaccines market report include:
- AstraZeneca PLC
- Bharat Biotech International Ltd.
- Boehringer Ingelheim International GmbH
- Daiichi Sankyo Co., Ltd.
- Emergent BioSolutions, Inc.
- GSK Plc
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis AG
- Novavax, Inc.
- Pfizer, Inc.
- Roche CustomBiotech
- Sanofi SA
- Serum Institute of India Pvt., Ltd.
- Takeda Pharmaceutical Co., Ltd.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca PLC
- Bharat Biotech International Ltd.
- Boehringer Ingelheim International GmbH
- Daiichi Sankyo Co., Ltd.
- Emergent BioSolutions, Inc.
- GSK Plc
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novartis AG
- Novavax, Inc.
- Pfizer, Inc.
- Roche CustomBiotech
- Sanofi SA
- Serum Institute of India Pvt., Ltd.
- Takeda Pharmaceutical Co., Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 391 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 86.9 Billion |
| Forecasted Market Value ( USD | $ 92.9 Billion |
| Compound Annual Growth Rate | 1.1% |
| Regions Covered | Global |
![Vaccine Market: Trends, Opportunities and Competitive Analysis [2024-2030] - Product Image](http://www.researchandmarkets.com/product_images/12459/12459681_60px_jpg/vaccine_market.jpg)
